Mizuho Remains Bullish on OraSure (OSUR) Ahead of Catalyst Despite AbbVie Termination
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
OraSure (OSUR) Investors Can Put Terminated AbbVie (ABBV) Agreement in Rear View as Other Opportunities About - BTIG
July 1, 2016 3:12 PM EDTBTIG affirms OraSure (Nasdaq: OSUR) at Buy with a price target of $8 following news of a terminated HCV co-promotion agreement earlier in the week.
Analyst Karen Koski noted the following key points on Friday:
While OSUR benefitted some from the agreement and the $3.4M in exclusivity payments recognized each... MoreOraSure (OSUR), AbbVie (ABBV) Terminate OraQuick HCV Rapid Antibody Test Agreement Early
July 1, 2016 6:20 AM EDTOraSure Technologies (Nasdaq: OSUR) announced today that OraSure Technologies and AbbVie (NYSE: ABBV) have mutually agreed to an early termination of their Master Program Services and Co-Promotion Agreement under which the companies have been co-promoting OraSures OraQuick HCV Rapid Antibody Test in the United States. The agreement was originally scheduled to continue through December 31, 2019 and will now end on December 31, 2016.
Under the agreement, which was signed in June 2014, OraSure granted exclusive rights to AbbVie to co-promote the OraQuick® HCV test in certain... More
OraSure Technologies (OSUR) on Watch Following Negative Blog Post
June 30, 2016 9:51 AM EDTBlogger Richard Pearson is out negative on OraSure Technologies (NASDAQ: OSUR); expects the stock to drop 35% or more next week. LINK
BTIG Reaffirms OraSure (OSUR) at 'Buy' Ahead of co-Promotion Agreement Decision with AbbVie (ABBV)
June 29, 2016 6:40 AM EDTBTIG affirms OraSure Technologies (Nasdaq: OSUR) with a Buy rating and $9 price target amid possible termination of the HCV co-promotion agreement with AbbVie (NYSE: ABBV).
Analyst Karen Koski commented today:
Beginning later this week (specifically on Thursday, 6/30), either OSUR or ABBV has the option of providing a six month notice of termination of the HCV Co-Promotion... More